Today: 17 May 2026
NIO Stock Price Rises as Shares Buck Tesla-Led Selloff After First-Ever Profit
20 March 2026
1 min read

NIO Stock Price Rises as Shares Buck Tesla-Led Selloff After First-Ever Profit

NEW YORK, March 19, 2026, 19:13 EDT

NIO Inc. picked up 1.2% on Thursday, closing at $5.89 and snapping a two-day skid. The stock pulled ahead even as the Nasdaq slipped and Tesla lost ground. Trading volume landed at roughly 29.9 million shares, notably under its 50-day average—hinting traders weren’t rushing in just yet.

The move is significant, with investors watching to see if NIO’s debut quarterly net profit has staying power in a challenging market. Last week, the company guided for first-quarter deliveries between 80,000 and 83,000 units. Vehicle margin stood at 18.1% in Q4, measuring profit per vehicle sale before accounting for broader costs.

XPeng’s U.S. shares moved up 2.1%, Li Auto ticked 0.3% higher, but Tesla dropped 3.2% after American regulators expanded their investigation into the company’s Full Self-Driving system. NIO sat in between on a choppy day for EV stocks, holding up better than a lot of high-growth names.

NIO is banking on bigger scale, tighter costs, and getting more cars out of China in 2026. President Qin Lihong put a number on it, targeting overseas sales in the thousands this year. But Chief Executive William Li flagged a persistent headache—memory chips. According to Li, the chip crunch could hike costs by 6,000 yuan to 10,000 yuan per car, and in the worst scenario, even force a production halt.

Li reported record quarterly deliveries for NIO, ONVO, and FIREFLY in its March 10 earnings statement. CFO Stanley Yu Qu called the fourth quarter’s non-GAAP operating profit of 1.25 billion yuan “a major milestone” for operating performance, referring to the company’s own adjusted earnings metric. SEC

Analysts aren’t convinced the reset is finished. On March 13, HSBC’s Yuqian Ding bumped NIO up to Buy from Hold and raised her price target to $6.80, citing “better visibility” for 2026 volume growth and a clearer path to stronger earnings as the automaker’s next product cycle approaches. Investing.com

The upside isn’t a done deal. DBS analysts Raphael Wut Hei Tse and Elizabelle Pang stuck to their Hold rating as of March 13, pointing to “sector headwinds” that might counteract improved operating leverage. They flagged a potential slowdown in China’s auto market and tough competition as the big risks. DBS Bank

Thursday’s move higher has the feel of a reprieve rather than a decisive surge. NIO lags its 52-week high by 26.6%, and now the spotlight turns to March demand. The challenge: hit those first-quarter delivery goals without eroding margins.

Stock Market Today

  • Understanding Tax-Loss Harvesting Amid Stock Market Gains
    May 16, 2026, 7:47 PM EDT. Tax-loss harvesting is gaining traction as the stock market surges, offering investors a strategy to offset capital gains by selling investments at a loss. This technique can reduce taxable income and boost after-tax returns. Wall Street professionals are increasingly adopting this approach to optimize portfolios in a high-gain environment. The method involves careful timing and selection of assets to comply with tax regulations while maintaining market positions. As tax considerations grow in importance, investors seek effective strategies like tax-loss harvesting to manage their liabilities amidst fluctuating markets.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock
Previous Story

NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy
Next Story

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Go toTop